X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3208) 3208
Newsletter (371) 371
Newspaper Article (153) 153
Publication (139) 139
Book Review (76) 76
Magazine Article (49) 49
Trade Publication Article (15) 15
Book Chapter (10) 10
Data Set (4) 4
Conference Proceeding (3) 3
Dissertation (2) 2
Paper (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple sclerosis (2334) 2334
humans (2232) 2232
interferon beta-1b (1457) 1457
clinical neurology (1263) 1263
female (1094) 1094
adult (1032) 1032
interferon (1032) 1032
interferon-beta - therapeutic use (1032) 1032
male (1017) 1017
index medicus (983) 983
multiple sclerosis - drug therapy (874) 874
interferon beta-1a (865) 865
interferon beta (728) 728
middle aged (721) 721
neurosciences (712) 712
double-blind (670) 670
biological response modifiers (551) 551
glatiramer acetate (522) 522
multiple sclerosis, relapsing-remitting - drug therapy (497) 497
treatment outcome (497) 497
neurology (493) 493
research (482) 482
care and treatment (452) 452
adjuvants, immunologic - therapeutic use (445) 445
magnetic resonance imaging (445) 445
placebo-controlled trial (429) 429
interferon-beta (392) 392
drug therapy (385) 385
disease progression (380) 380
therapy (358) 358
multicenter (352) 352
disability (340) 340
interferon-beta - administration & dosage (310) 310
interferon-beta - adverse effects (304) 304
multiple sclerosis - immunology (293) 293
immunology (283) 283
medicine & public health (267) 267
multiple sclerosis - therapy (258) 258
immunologic factors - therapeutic use (256) 256
pharmacology & pharmacy (246) 246
disability evaluation (238) 238
multiple-sclerosis (237) 237
immunosuppressive agents - therapeutic use (234) 234
adolescent (231) 231
clinical trials (226) 226
neutralizing antibodies (220) 220
time factors (220) 220
medical research (218) 218
disease (214) 214
patients (214) 214
recurrence (214) 214
peptides - therapeutic use (213) 213
health aspects (209) 209
multiple sclerosis - diagnosis (198) 198
psychiatry (198) 198
follow-up studies (196) 196
animals (195) 195
interferon-beta - immunology (195) 195
mri (195) 195
multiple sclerosis - pathology (187) 187
medicine, experimental (186) 186
brain - pathology (182) 182
young adult (182) 182
medicine, general & internal (180) 180
analysis (175) 175
adjuvants, immunologic - administration & dosage (173) 173
interferon-beta - pharmacology (168) 168
multiple sclerosis - physiopathology (168) 168
aged (162) 162
pharmaceutical industry (162) 162
clinical trials as topic (160) 160
natalizumab (160) 160
diagnostic-criteria (159) 159
medicine (157) 157
risk factors (157) 157
dosage and administration (154) 154
retrospective studies (152) 152
studies (151) 151
development and progression (150) 150
adjuvants, immunologic - adverse effects (149) 149
follow-up (146) 146
experimental autoimmune encephalomyelitis (144) 144
cytokines (141) 141
drugs (140) 140
research article (140) 140
prospective studies (137) 137
trial (137) 137
natural-history (136) 136
neuroradiology (135) 135
recombinant proteins - therapeutic use (131) 131
antibodies (130) 130
reports (130) 130
central-nervous-system (129) 129
remitting multiple-sclerosis (127) 127
multiple sclerosis, relapsing-remitting - immunology (126) 126
usage (126) 126
ifn-beta (125) 125
efficacy (124) 124
quality of life (123) 123
secondary progressive ms (122) 122
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3532) 3532
German (102) 102
Spanish (43) 43
Russian (40) 40
French (32) 32
Japanese (13) 13
Polish (11) 11
Czech (7) 7
Hungarian (5) 5
Portuguese (5) 5
Croatian (3) 3
Dutch (3) 3
Turkish (3) 3
Italian (2) 2
Chinese (1) 1
Danish (1) 1
Korean (1) 1
Persian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 2011, Volume 307, Issue 1, pp. 120 - 126
Abstract Background Low adherence to treatment in Multiple Sclerosis (MS) has been shown to lead to poor health outcomes. Various strategies to improve... 
Neurology | Multiple Sclerosis | Adherence | Interferon beta-1b | Coping styles | Nurses | Autoinjector devices | MEDICATION | DEPRESSION SCALE | ANXIETY | RELIABILITY | NEUROSCIENCES | CLINICAL NEUROLOGY | THERAPY | PEOPLE | INTERFERONS | VALIDITY | SPECIALIST | Multiple sclerosis | Biological response modifiers | Analysis | Interferon beta
Journal Article
NEUROLOGY, ISSN 0028-3878, 10/2010, Volume 75, Issue 16, pp. 1423 - 1427
Background: Interferon-beta-1b (IFN beta-1b) has been used to prevent exacerbation of relapsing-remitting multiple sclerosis (RRMS) including optic-spinal... 
THERAPY | MULTIPLE-SCLEROSIS | MARKER | SERUM | INTERFERON-BETA-1B | DIAGNOSTIC-CRITERIA | MYASTHENIA-GRAVIS | CLINICAL NEUROLOGY
Journal Article
Journal of Neurology, ISSN 0340-5354, 12/2017, Volume 264, Issue 12, pp. 2436 - 2449
Cognitive impairment (CI) affects 40–65% of multiple sclerosis (MS) patients. This study attempted evaluating the effects of fingolimod and interferon beta-1b... 
Neurology | Neurosciences | Interferon beta-1b | Medicine & Public Health | Fingolimod | Brief repeatable battery test | Brain atrophy | Delis–Kaplan executive function test | Neuroradiology | Cognitive impairment | ORAL FINGOLIMOD | NATALIZUMAB | CLINICAL NEUROLOGY | IMPAIRMENT | DECLINE | EXECUTIVE FUNCTION SYSTEM | Delis-Kaplan executive function test | PLACEBO-CONTROLLED TRIAL | DYSFUNCTION | VALIDITY | Cognition Disorders - diagnostic imaging | Humans | Middle Aged | Male | Depression - etiology | Young Adult | Depression - drug therapy | Cognition Disorders - etiology | Statistics, Nonparametric | Electrocardiography | Adult | Female | Fingolimod Hydrochloride - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - complications | Disability Evaluation | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Treatment Outcome | Cognition Disorders - drug therapy | Neuropsychological Tests | Magnetic Resonance Imaging | Pilot Projects | Interferon beta-1b - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adolescent | Longitudinal Studies | Executive Function - drug effects | Immunologic Factors - therapeutic use | Complications and side effects | Usage | Multiple sclerosis | Care and treatment | Magnetic resonance imaging | Patient outcomes | Dosage and administration | Neuroimaging | Executive function | Nuclear magnetic resonance--NMR | Cognitive ability | Gadolinium | Interferon | Clinical outcomes | Original Communication
Journal Article
NEUROLOGY, ISSN 0028-3878, 04/2012, Volume 78, Issue 17, pp. 1315 - 1322
Objective: To examine the effects of interferon beta (IFN beta)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the... 
REMITTING MULTIPLE-SCLEROSIS | OXIDATIVE STRESS | MULTICENTER | DANISH PATIENTS | DOUBLE-BLIND | MITOCHONDRIAL DYSFUNCTION | DEATH | PLACEBO-CONTROLLED TRIAL | CLINICAL NEUROLOGY | INTERFERON BETA-1A THERAPY
Journal Article
Journal Article
Neurology, ISSN 0028-3878, 11/2004, Volume 63, Issue 10, pp. 1779 - 1787
Journal Article